Replies to post #49279 on Medizone Intl. (fka MZEIQ)

[fcmboca]

Actually there is a company that has a process for removing pathogens from the blood supply approved by the FDA and regulators in many other countries around the world . Company is Cerus Corp. and trades as CERS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development.

[futurist7]

YES, "Not very bright" is one option for sure. Also too trusting that authentic honest governance was at the helm, also that a serious Canadian doctor/researcher was leading the way and kept things on the up and up. Only few of the wise saw the enormous potholes, if not the sinkholes springing up all around.

[teq0904]

Holding onto something that you own is effectively investing in it, so if your claim below is valid, then it applies to all bag holders. "People who invested in the company after the blood purification fiasco just weren't very bright."

No competitor bid, so it likely has no value. Could be due to other competitors new tech forcing out the weak.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147765571